Skip to main content
2025 National Biotechnology Conference Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Steven W. Louie, M.S. (he/him/his)

Director
Medicilon -US Corp
Lexington, Massachusetts

Steven W. Louie is the Director of DMPK at Medicilon U.S. based out of Lexington, MA. He is serving dual roles as the U.S. DMPK Lab Head as well as the Client-Engagement Subject Matter Expert (SME). His focus lies in advancing mechanistic studies crucial for in vitro/in vivo extrapolation (IVIVE), a pivotal aspect of pharmacokinetics to support human dose projections. Our team's mission is to advance our client's preclinical drug candidates from High Throughput (HT) in vitro Tier 1 assays to in vivo PK/PD towards IND-filing.

Prior to joining Medicilon Steven, was an Associate Director at Moderna Therapeutics (Cambridge, MA) hired to build the in vitro DMPK lab. Prior to leaving Moderna, he served as DMPK Lead (Project Rep) for Rare Diseases. Steven has 20+ years of preclinical ADME/DMPK discovery and development experience in Big Pharma including GSK, Merck, Amgen, and Novartis working with small molecules and newer biologics, such as Peptides, ADCs, PROTACs, LNP-mRNA, siRNA, and others. Steven serves and Chairs multiple conference steering committees including the Boston Society Gene & Cell Therapy, NE-ADME, AAPS PharmSci360, and is delighted to Co-Chair the 2025 Program Track for 2025 NBC Conference held in Boston.

Disclosure information not submitted.

Presentation(s):